Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Keryx Biopharmaceuticals    KERX

Delayed Quote. Delayed  - 10/25 10:00:00 pm
4.71 USD   --.--%
10/18 KERYX BIOPHARMA : KERX) Files An 8-K
10/14 KERYX BIOPHARMA : Announces Presentations of Data at the American So..
10/01 KERYX 72 HOUR D : Approximately 72 Hours Remain; Former Louisiana At..
News SummaryMost relevantAll newsSector news 

Keryx Biopharmaceuticals : Traders Favorite: Keryx Biopharmaceuticals, McDonald's Corporation, Merck & Co, Hertz Global Holdings

share with twitter share with LinkedIn share with facebook
share via e-mail
04/22/2013 | 08:05pm CEST

NEW YORK, April 22, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Keryx Biopharmaceuticals, McDonald's Corporation, Merck & Co, Hertz Global Holdings.

Keryx Biopharmaceuticals (NASDAQ:KERX) shares gained 5.48% to $8.47. The company, on March 11, announced its results for the fourth quarter and year ended December 31, 2012. The net loss for the 4th quarter ended December 31, 2012 was $6.6 million, or $0.09 per share versus $8.4 million for quarter 2011, representing a decrease of $1.8 million and Net loss for the year ended December 31, 2012, was $22.7 million versus $28.1 million for the year ended December 31, 2011, representing a decrease in net loss of $5.4 million.

At December 31, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $14.7 million, as compared to $39.5 million at December 31, 2011.

Has KERX Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=KERX (OR Just copy and paste the link)

McDonald's Corporation(NYSE:MCD) shares decreased 1.13% to $98.80. The company, on April 19, posted first-quarter profit that was little changed as same-store sales dropped in the U.S. for the first time since 2003 amid soft global demand. Net income was about $1.27 billion, or $1.26 share, compared with $1.27 billion, or $1.23, a year earlier. Analysts projected $1.26, the average of 29 estimates compiled by analyst.

Has MCD Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MCD (OR Just copy and paste the link)

Additionally, MCD?s stock had its ?buy? rating restated by analysts at Janney Montgomery Scott in a research report issued to clients and investors on April 16. They currently have a $115.00 price target on the stock.

Merck & Co., Inc.(NYSE:MRK) shares fell 0.38% to $47.31. The company, on April 1st reported that it will hold its first-quarter 2013 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Wednesday, May 1.

Has MRK Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MRK (OR Just copy and paste the link)

Additionally, the company, on April 10, announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration (FDA).

Hertz Global Holdings, Inc. (NYSE:HTZ) shares decreased 0.76% to $23.54. The company, on April 16, agreed to acquire a 20% stake in Beijing-based China Auto Rental Holdings Inc. to expand its presence in China's car-rental market. Financial terms weren't disclosed.

How Should Investors Trade HTZ Now? Get Free Trend Analysis Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=HTZ (OR Just copy and paste the link)

Additionally, the company, on April 8, announced that its wholly-owned subsidiary, The Hertz Corporation ("Hertz"), has successfully completed a repricing of its currently outstanding $1,372 billion senior secured tranche B term loan facility. As part of the repricing, the tranche B term loans will be replaced by new tranche B-2 term loans.

About bestdarnpennystocks.com
bestdarnpennystocks.com?s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

The assembled information disseminated by bestdarnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. bestdarnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in bestdarnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
1419 Westwood Blvd Los Angeles, CA

© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
10/17 KERYX BIOPHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Regul..
10/14 KERYX BIOPHARMACEUTICALS : Announces Presentations of Data at the American Socie..
10/01 KERYX 72 HOUR DEADLINE ALERT : Approximately 72 Hours Remain; Former Louisiana A..
09/30 KERYX BIOPHARMACEUTICALS : 3-DAY DEADLINE: Khang & Khang LLP Announces Securitie..
09/29 KERYX BIOPHARMACEUTICALS : Researchers Submit Patent Application, "Ferric Citrat..
09/29 DEADLINE ALERT : Rigrodsky & Long, P.A. Reminds Shareholders Of Keryx Biopharmac..
09/29 OCTOBER 3RD DEADLINE IN LAWSUIT FOR : KERX) announced by Shareholders Foundatio..
09/28 KERYX BIOPHARMACEUTICALS : OCTOBER 3 DEADLINE: Lundin Law PC Announces Securitie..
09/28 KERYX BIOPHARMACEUTICALS : DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Re..
More news
Sector news : Bio Therapeutic Drugs
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
10/03 Keryx Biopharmaceuticals Is Likely To Fully Recover From August
08/26 KERYX BIOPHARMACEUTICALS : A Highly Asymmetric Bet For The Long-Term Investor
08/15 Tracking David Abrams' Abrams Capital Management Portfolio - Q2 2016 Update
08/13 Tracking Seth Klarman's Baupost Group Holdings - Q2 2016 Update
08/08 Why Keryx Biopharma's Auryxia Could Become The Largest Selling Phosphate-Bind..
Financials ($)
Sales 2016 26,1 M
EBIT 2016 -87,6 M
Net income 2016 -131 M
Finance 2016 92,3 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 15,6x
EV / Sales 2017 7,50x
Capitalization 499 M
More Financials
Duration : Period :
Keryx Biopharmaceuticals Technical Analysis Chart | KERX | US4925151015 | 4-Traders
Full-screen chart
Technical analysis trends KERYX BIOPHARMACE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 10
Average target price 6,71 $
Spread / Average Target 43%
Consensus details
EPS Revisions
More Estimates Revisions
Gregory P. Madison Chief Executive Officer & Director
John P. Butler Chairman
Scott A. Holmes Chief Financial Officer
John F. Neylan Chief Medical Officer
Kevin J. Cameron Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.-2.20%118 810
GILEAD SCIENCES, INC.-26.72%97 853
More Results